Hyperglycemia News and Research

RSS
Hyperglycemia occurs when you have a higher than usual level of glucose in your blood. This can happen shortly after you have eaten a big meal and is not a problem if your glucose level returns to normal. Cells remove glucose from the blood in response toinsulin. If your pancreas doesn't make enough insulin, glucose can't enter the cells and remains in the blood. Blood glucose levels can also get too high if cells areunable to respond to insulin properly (insulinresistance). Without glucose, your cells are unable to make energy and can't function properly.
JDRF and Animas partner to develop an automated system for better control of type 1 diabetes

JDRF and Animas partner to develop an automated system for better control of type 1 diabetes

FDA yet to review MannKind’s NDA for insulin therapy

FDA yet to review MannKind’s NDA for insulin therapy

MicroCHIPS raises $16.5 million to fund for diabetes and osteoporosis programs

MicroCHIPS raises $16.5 million to fund for diabetes and osteoporosis programs

Biodel submits NDA to FDA for clearance to market VIAject

Biodel submits NDA to FDA for clearance to market VIAject

Initial data from REVLIMID Phase III trial in multiple myeloma patients announced

Initial data from REVLIMID Phase III trial in multiple myeloma patients announced

ZYPREXA RELPREVV approved by FDA

ZYPREXA RELPREVV approved by FDA

Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA

Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

Study data of REVLIMID-dexamethasone combination therapy for high-risk smoldering multiple myeloma

Study data of REVLIMID-dexamethasone combination therapy for high-risk smoldering multiple myeloma

Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients

Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients

Discovery presents a vital step towards efficient treatment of vascular injuries

Discovery presents a vital step towards efficient treatment of vascular injuries

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

FDA approves once-daily SEROQUEL XR Extended Release Tablets

FDA approves once-daily SEROQUEL XR Extended Release Tablets

New data demonstrating the strength of Novartis' hematology portfolio to be presented

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Antipsychotic medications increase the levels of inflammation markers, find researchers

Antipsychotic medications increase the levels of inflammation markers, find researchers

Research study on the function of orexin neurons in brain

Research study on the function of orexin neurons in brain

FDA approves Pfizer's Geodon Capsules for the adjunctive maintenance treatment of bipolar disorder

FDA approves Pfizer's Geodon Capsules for the adjunctive maintenance treatment of bipolar disorder

FDA approves sNDA for pediatric autism drug ABILIFY

FDA approves sNDA for pediatric autism drug ABILIFY

Xeomin receives approval for post-stroke spasticity of upper limb in European countries

Xeomin receives approval for post-stroke spasticity of upper limb in European countries

CPEX Pharmaceuticals announces third-quarter results; reports net loss of $872,000

CPEX Pharmaceuticals announces third-quarter results; reports net loss of $872,000

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.